Business Context and Reporting Period
This Form 8-K filing by Genesco Inc. reports on events occurring on January 16, 2009, with the report filed on January 22, 2009. The filing addresses Item 5.02 regarding the appointment of certain officers and their compensatory arrangements for the fiscal year ending January 30, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on executive compensation details.
| Named Executive Officer | Title | Base Salary | Target Incentive Award |
|---|---|---|---|
| Hal N. Pennington | Chairman | $225,000 | $75,000 |
| Robert J. Dennis | President and CEO | $778,500 | $622,800 |
| James S. Gulmi | SVP and CFO | $408,972 | $245,383 |
| Jonathan D. Caplan | SVP | $330,000 | $198,000 |
| James C. Estepa | SVP | $555,330 | $333,198 |
Material Changes
The Compensation Committee established base salaries and target annual incentive awards for the fiscal year 2010 under the Amended and Restated EVA Incentive Compensation Plan. The filing does not explicitly state percentage changes from the prior period for these specific figures.
Guidance, Outlook, and Risks
There is no financial guidance, outlook, or discussion of risks and contingencies in this filing. A specific note regarding calculation methodology states that Robert J. Dennis's incentive award for fiscal 2010 will be calculated as though he were a corporate staff participant in the EVA Incentive Plan, whereas all other named executive officers are standard participants.
Investor Verification Checklist
- Verify the total compensation cost impact of the new salary and incentive targets for fiscal 2010.
- Confirm the specific performance metrics tied to the EVA Incentive Plan to understand the likelihood of the target awards being achieved.
- Review the "corporate staff participant" calculation method for the CEO to ensure it aligns with shareholder interests compared to standard executive participation.
- Check subsequent filings for actual performance results against these targets.